Vernakalant (oral) prevention of atrial fibrillation recurrence post-conversion study.

Trial Profile

Vernakalant (oral) prevention of atrial fibrillation recurrence post-conversion study.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Vernakalant (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Cardiome Pharma
  • Most Recent Events

    • 31 Aug 2009 Results reported at the European Society of Cardiology (ESC) annual meeting.
    • 14 Jul 2008 Final results reported by Cardiome.
    • 14 Jul 2008 Status changed from in progress to completed as reported by Cardiome.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top